OncoMASTER and NOVO Genomics Sign MOU for Groundbreaking Precision Oncology Feasibility Studies in Saudi Arabia

Seoul, South Korea & Riyadh, Saudi Arabia; 19 November 2024: OncoMASTER, a Korea-based leader in precision oncology, and NOVO Genomics, a pioneering Saudi biotech company, have signed a Memorandum of Understanding (MOU) to launch several advanced feasibility studies in personalized cancer treatment for Saudi patients. This collaboration represents a significant step in harnessing AI-driven oncology insights to bring precision medicine to the Middle East and positions Saudi Arabia as a regional leader in advanced cancer care.

“We at NOVO Genomics are thrilled to partner with OncoMASTER, bringing their transformative AI technology to Saudi Arabia. This collaboration will allow us to improve cancer care outcomes and establish the Kingdom as a leader in precision oncology,” said Abdulelah Alhawsawi, CEO of NOVO Genomics. “This MOU represents a significant step forward for our mission to deliver world-class healthcare solutions aligned with Saudi Vision 2030.

This MOU reflects a pivotal collaboration in precision oncology, with both OncoMASTER and NOVO Genomics dedicated to advancing healthcare through innovation. By integrating OncoMASTER’s predictive models with NOVO Genomics’ local genomic expertise, the partnership aims to bring personalized cancer treatment options to Saudi patients and enhance clinical trial accessibility in the region. This MOU not only strengthens Saudi Arabia’s leadership role in precision oncology but also paves the way for skill development in AI and genomics, potentially creating high-value jobs and contributing to a robust biotech ecosystem.

“We are excited to partner with NOVO Genomics and to bring the potential of OncoMASTER’s AI-driven oncology models to Saudi Arabia. This collaboration will not only help improve patient outcomes but could also serve as a framework for broader precision medicine applications in the Middle East,” said Dr. Woo Young Jang, CEO of OncoMASTER.

Through this strategic MOU, OncoMASTER and NOVO Genomics will explore multiple collaborative initiatives to bring data-driven oncology solutions to Saudi Arabia, including:

1. implement and evaluate OncoMASTER’s predictive AI model, which classifies colorectal cancer patients into treatment groups likely to benefit from specific therapies;
2. feasibility study on an AI-based clinical trial matching solution, ultimately improving patient access to cutting-edge treatments; and
3. collaboration on OncoMASTER’s other AI-driven solutions, designed to enhance precision oncology capabilities by integrating genomic and clinical data, paving the way for further personalization in cancer treatment.

Inspired by the success of South Korea’s K-MASTER, the MOU includes discussions on establishing the “S-MASTER” project—Saudi Arabia’s version of the K-MASTER initiative. The S-MASTER project aims to create one of the region’s largest cancer genomics databases, specifically tailored to the genetic profiles of Saudi patients. This initiative would support innovative cancer therapies and personalized treatment options in Saudi Arabia, driving forward Saudi Vision 2030’s goal of a world-class healthcare system.

-ENDS-

About OncoMASTER

Founded in South Korea, OncoMASTER is a leading precision oncology company that combines AI and genomics to deliver breakthrough healthcare solutions. The company’s technology, rooted in the K-MASTER project, harnesses data from over 10,000 advanced cancer patients, making it the largest cancer genomics initiative in Korea. By accurately predicting therapeutic responses, OncoMASTER is paving the way for individualized treatments in oncology setting new standards in personalized cancer care.

About NOVO Genomics

NOVO Genomics is a Saudi biotech company at the forefront of genomics and multi-omics applications in healthcare. Focused on localizing state-of-the-art technologies, NOVO Genomics utilizes advanced analytics and data mining to drive health and wellness improvements in Saudi Arabia and the broader region. Through pioneering genomics insights, NOVO Genomics is committed to transforming patient care and fostering innovation in the life sciences sector.

For more information, please contact:

OncoMASTER

[Media Contact Information] Cheol Hoon Seong, Chief Business Officer

[Phone Number] 82-10-5130-8147

[Email Address] [email protected]

NOVO Genomics

[Media Contact Information] Ishradeen Ali

[Phone Number] +966 53 508 1750

[Email Address] [email protected]